Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederroche.com
Roche Media News
Get the latest updates from Roche Media News directly as they happen.
Follow now 291 followers
Latest posts
Last updated 1 day ago
Roche’s Vabysmo improved vision in underrepresented populations with diabetic macular edema (DME) in a first-of-its-kind study
1 day ago
The ELEVATUM study showed clinically meaningful improvement in vision and reduction in...
Majority of children with spinal muscular atrophy (SMA) treated with Roche’s Evrysdi are able to sit, stand and walk independently, two-year data demonstrate
6 days ago
Positive data confirm Evrysdi efficacy and safety in children first treated pre-symptomatically...
FDA approves Roche’s Itovebi, a targeted treatment for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation
9 days ago
Approval is based on Phase III INAVO120 results, showing the Itovebi™ (inavolisib)-based...
Roche obtains CE certification for the first companion diagnostic to identify patients with gastric and gastroesophageal junction cancer eligible for targeted treatment with VYLOY
10 days ago
The new VENTANA CLDN18 (43-14A) RxDx Assay helps fulfil an unmet medical...
Positive phase III results for Roche’s Gazyva/Gazyvaro show superiority to standard therapy alone in people with lupus nephritis
24 days ago
Positive phase III results for Roche’s Gazyva/Gazyvaro show superiority to standard therapy...
Roche launches the first test to use its breakthrough TAGS technology for high throughput, simultaneous detection of 12 respiratory viruses
26 days ago
New TAGS (Temperature-Activated Generation of Signal) technology enables up to 15 targets...
WHO endorses dual-stain cytology (CINtec PLUS) testing in its cervical cancer prevention guidelines, advancing patient care and underlining Roche’s role in pioneering cervical cancer solutions
27 days ago
Roche’s CINtec PLUS Cytology is the only FDA-approved and CE-marked dual-stain test...
Positive phase III results show Xofluza significantly reduces the transmission of influenza viruses
about 1 month ago
Data from the CENTERSTONE study shows single-dose Xofluza reduces transmission of influenza...
FDA approves OCREVUS ZUNOVO™ as the first and only twice-a-year 10-minute subcutaneous injection for people with relapsing and progressive multiple sclerosis
about 1 month ago
OCREVUS ZUNOVO™ has the potential to expand treatment options to centres without...
FDA approves Roche’s Tecentriq Hybreza, the first and only subcutaneous anti-PD-(L)1 cancer immunotherapy
about 1 month ago
Tecentriq Hybreza provides patients and physicians with greater flexibility of treatment options...
Roche opens Pharma Research and Development Center in Basel to accelerate scientific innovation
about 1 month ago
Switzerland’s most innovative research and development center underscores Roche’s long-term investment in...
Roche’s fenebrutinib demonstrated near-complete suppression of disease activity and disability progression for up to 48 weeks in patients with relapsing multiple sclerosis
about 2 months ago
New Phase II data show vast majority of patients experiencing no relapses...